BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
China CAR T
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Thursday, May 2, 2024
See today's BioWorld
Home
» China’s Luye Pharma steps up M&A with $263M buyout of Acino
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
China’s Luye Pharma steps up M&A with $263M buyout of Acino
Dec. 9, 2016
By
Pearl Liu
No Comments
HONG KONG – In yet another of a growing list of acquisitions, Chinese drugmaker Luye Pharma Group Ltd. (2186.HK) has inked an agreement to acquire Swiss-based Acino Holdings’ transdermal drug delivery systems (TDS) business.
BioWorld